DGIdb - GLYBURIDE Drug Record

GLYBURIDE chembl:CHEMBL472 Approved

Alternate Names:

DIABETAMIDE 5
MALIX
GLYNASE
CALABREN
GLIBENCLAMIDE
HB 419
U-26452
U-26,45
GLYNASE PRESTAB
MICRONASE
DIABETA
LIBANIL
DAONIL
DIABETAMIDE 2.5
GLYBURIDE
LEDERGLIB
HB-419
EUGLUCON
SEMI-DAONIL
GLYBURIDE (MICRONIZED)
GLIKEN
DIABETA®
GLIBENCLAMIDUM
1-(P-(2-(5-CHLORO-2-METHOXYBENZAMIDO)ETHYL)BENZENESULFONYL)-3-CYCLOHEXYLUREA
5-CHLORO-N-(2-(4-((((CYCLOHEXYLAMINO)CARBONYL)AMINO)SULFONYL)PHENYL)ETHYL)-2-METHOXYBENZAMIDE
1-((P-(2-(5-CHLORO-O-ANISAMIDO)ETHYL)PHENYL)SULFONYL)-3-CYCLOHEXYLUREA
GLIBENCLAMIDA
GLYNASE®
chembl:CHEMBL472
chemidplus:10238-21-8
drugbank:01016
pubchem.compound:3488
rxcui:4815

Drug Info:

Drug Class	hypoglycemic agents
Year of Approval	1984
FDA Approval	1984
Drug Class	small molecule
Drug Indications	Hypoglycemic Agents
FDA Approval	approved
Drug Indications	antidiabetic

(7 More Sources)

Publications:

Li Q et al., 2014, KCNJ11 E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patients., Clin Exp Pharmacol Physiol
Klen J et al., 2014, CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients., Eur J Clin Pharmacol
Javorsky M et al., 2012, KCNJ11 gene E23K variant and therapeutic response to sulfonylureas., Eur J Intern Med
Sesti G et al., 2006, The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes., J Clin Endocrinol Metab
Gloyn AL et al., 2001, Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53)., Diabet Med
Jabůrek et al., 1998, State-dependent inhibition of the mitochondrial KATP channel by glyburide and 5-hydroxydecanoate., J. Biol. Chem.
Babenko et al., 2002, SUR-dependent modulation of KATP channels by an N-terminal KIR6.2 peptide. Defining intersubunit gating interactions., J. Biol. Chem.
Serrano-Martín et al., 2006, Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis., Antimicrob. Agents Chemother.
Ueda et al., 1999, Cooperative binding of ATP and MgADP in the sulfonylurea receptor is modulated by glibenclamide., Proc. Natl. Acad. Sci. U.S.A.
Hambrock et al., 2002, Four novel splice variants of sulfonylurea receptor 1., Am. J. Physiol., Cell Physiol.
Nielsen et al., 2002, 6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells., J. Med. Chem.
Hambrock et al., 2002, Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides., Br. J. Pharmacol.
Dabrowski et al., 2002, The novel diazoxide analog 3-isopropylamino-7-methoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide is a selective Kir6.2/SUR1 channel opener., Diabetes
Zhang YF et al., 2005, [Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]., Yao Xue Xue Bao
Abu-Hamdah et al., 2004, Regulation of the water channel aquaporin-1: isolation and reconstitution of the regulatory complex., Cell Biol. Int.
Sireci et al., 1999, Effects of glyburide-cyclosporin A interaction on interleukin-2 production in rats., Immunopharmacol Immunotoxicol
Carette C et al., 2011, Diabetes mellitus and glucose-6-phosphate dehydrogenase deficiency: from one crisis to another., Diabetes Metab
Vinzio S et al., 2004, Glibenclamide-induced acute haemolytic anaemia revealing a G6PD-deficiency., Diabetes Res Clin Pract
Meloni G et al., 1996, Glyburide-induced acute haemolysis in a G6PD-deficient patient with NIDDM., Br J Haematol
Youngster I et al., 2010, Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review., Drug Saf
Kharbanda C et al., 2015, Antidiabetic effect of novel benzenesulfonylureas as PPAR-γ agonists and their anticancer effect., Bioorg Med Chem Lett
Spraggs C et al., 2007, Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar., Pharmacogenet Genomics
Ren Q et al., 2016, Genetic and Clinical Predictive Factors of Sulfonylurea Failure in Patients with Type 2 Diabetes., Diabetes Technol Ther
Kern et al., 1993, Increased muscle glucose uptake in response to chronic glyburide treatment is not related to changes in glucose transporter (GLUT4) protein., Int. J. Biochem.
Lee et al., 2005, Inhibition of Na+-K+ pump and L-type Ca2+ channel by glibenclamide in Guinea pig ventricular myocytes., J. Pharmacol. Exp. Ther.
Zhou et al., 2002, Probing an open CFTR pore with organic anion blockers., J. Gen. Physiol.
Larsen et al., 2003, Beta-adrenergic receptors couple to CFTR chloride channels of intercalated mitochondria-rich cells in the heterocellular toad skin epithelium., Biochim. Biophys. Acta
Reddy et al., 2002, Effect of anion transport blockers on CFTR in the human sweat duct., J. Membr. Biol.
Jiang et al., 2003, Pleural surface fluorescence measurement of Na+ and Cl- transport across the air space-capillary barrier., J. Appl. Physiol.

GLYBURIDE AQP1

Interaction Score: 2.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14759764

Sources:
NCI
GLYBURIDE ABCC8

Interaction Score: 2.08

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name glyburide + metformin,Glucovance

Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker

PMIDs:
12213829 17015627 9990013 12107069 12213059 12145099 12031979

Sources:
TdgClinicalTrial ChemblInteractions TTD
GLYBURIDE KCNJ11

Interaction Score: 1.34

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand None

PMIDs:
25115353 24442125 22385882 16595597 11318841 9593694

Sources:
TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB
GLYBURIDE SCNN1B

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18004211

Sources:
PharmGKB
GLYBURIDE CFTR

Interaction Score: 0.92

Interaction Types & Directionality:

antagonist (inhibitory)

blocker (inhibitory)

Interaction Info:

Specific Action of the Ligand None

Endogenous Drug? False

PMIDs:
15365090 12407077 14729151 12202948 12391048

Sources:
GuideToPharmacology
GLYBURIDE ABCC5

Interaction Score: 0.89

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27403931

Sources:
PharmGKB
GLYBURIDE KCNJ1

Interaction Score: 0.51

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TEND
GLYBURIDE KCNJ8

Interaction Score: 0.44

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand None

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology
GLYBURIDE G6PD

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21147013 15126005 8562390 20701405

Sources:
PharmGKB FDA
GLYBURIDE IL2

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10466081

Sources:
NCI
GLYBURIDE SLC2A4

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8224371

Sources:
NCI
GLYBURIDE SLCO2B1

Interaction Score: 0.15

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
None found

Sources:
GuideToPharmacology
GLYBURIDE PPARG

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26384286

Sources:
DTC
GLYBURIDE CYP2C9

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24442125 16342679

Sources:
DTC PharmGKB
GLYBURIDE NR1I2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
GLYBURIDE CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
GLYBURIDE CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
GLYBURIDE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: GLIBENCLAMIDE
- Version: 01-August-2011
Alternate Names:

GLIBENCLAMIDE Primary Drug Name

Drug Info:

Year of Approval 1984

Drug Class hypoglycemic agents

Publications:
TdgClinicalTrial: GLIBENCLAMIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Hypoglycemic Agents

Drug Class small molecule

FDA Approval 1984

Publications:
TdgClinicalTrial: GLYBURIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antidiabetic

Drug Class Small molecule

FDA Approval approved

Publications:

NCI: GLYBURIDE

Version: 14-September-2017

Alternate Names:

C29076 NCI drug code

Drug Info:

Publications:

Abu-Hamdah et al., 2004, Regulation of the water channel aquaporin-1: isolation and reconstitution of the regulatory complex., Cell Biol. Int.

Sireci et al., 1999, Effects of glyburide-cyclosporin A interaction on interleukin-2 production in rats., Immunopharmacol Immunotoxicol

Kern et al., 1993, Increased muscle glucose uptake in response to chronic glyburide treatment is not related to changes in glucose transporter (GLUT4) protein., Int. J. Biochem.

DTC: GLYBURIDE
- Version: 02-September-2020
Alternate Names:

CHEMBL472 ChEMBL Drug ID

Drug Info:

Publications:

Kharbanda C et al., 2015, Antidiabetic effect of novel benzenesulfonylureas as PPAR-γ agonists and their anticancer effect., Bioorg Med Chem Lett

PharmGKB: glibenclamide

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Klen J et al., 2014, CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients., Eur J Clin Pharmacol

Sesti G et al., 2006, The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes., J Clin Endocrinol Metab

Gloyn AL et al., 2001, Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53)., Diabet Med

TTD: Glibenclamide
- Version: 2020.06.01
Alternate Names:

D05LYX TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 135650306
- Version: 29-September-2020
Alternate Names:

GLIBENCLAMIDE GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL472
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL472
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
FDA: Glyburide
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Novel drug target	Established target
Trial Name	glyburide + metformin,Glucovance
Mechanism of Interaction	Sulfonylurea receptor 1, Kir6.2 blocker

Direct Interaction?	True
Endogenous Drug?	False
Specific Action of the Ligand	None

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False

blocker (inhibitory)
inhibitor (inhibitory)

antagonist (inhibitory)
blocker (inhibitory)

GLYBURIDE Drug Record

GLYBURIDE chembl:CHEMBL472 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14759764

Sources: NCI

Interaction Types & Directionality: blocker (inhibitory)

Interaction Info: Novel drug target Established target Trial Name glyburide + metformin,Glucovance Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker

PMIDs: 12213829 17015627 9990013 12107069 12213059 12145099 12031979

Sources: TdgClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality: blocker (inhibitory) inhibitor (inhibitory)

Interaction Info: Direct Interaction? True Endogenous Drug? False Specific Action of the Ligand None

PMIDs: 25115353 24442125 22385882 16595597 11318841 9593694

Sources: TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18004211

Sources: PharmGKB

Interaction Types & Directionality: antagonist (inhibitory) blocker (inhibitory)

Interaction Info: Specific Action of the Ligand None Endogenous Drug? False

PMIDs: 15365090 12407077 14729151 12202948 12391048

Sources: GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27403931

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand None Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21147013 15126005 8562390 20701405

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10466081

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8224371

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False

PMIDs: None found

Sources: GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26384286

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24442125 16342679

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

TEND: GLIBENCLAMIDE

Alternate Names: GLIBENCLAMIDE Primary Drug Name

Drug Info: Year of Approval 1984 Drug Class hypoglycemic agents

Interaction Types & Directionality:

n/a

PMIDs:
14759764

Sources:
NCI

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name glyburide + metformin,Glucovance

Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker

PMIDs:
12213829 17015627 9990013 12107069 12213059 12145099 12031979

Sources:
TdgClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand None

PMIDs:
25115353 24442125 22385882 16595597 11318841 9593694

Sources:
TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18004211

Sources:
PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

blocker (inhibitory)

Interaction Info:

Specific Action of the Ligand None

Endogenous Drug? False

PMIDs:
15365090 12407077 14729151 12202948 12391048

Sources:
GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
27403931

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand None

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
21147013 15126005 8562390 20701405

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
10466081

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8224371

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
26384286

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
24442125 16342679

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

GLIBENCLAMIDE Primary Drug Name

Drug Info:

Year of Approval 1984

Drug Class hypoglycemic agents

Drug Info:

Drug Indications Hypoglycemic Agents

Drug Class small molecule

FDA Approval 1984

Drug Info:

Drug Indications antidiabetic

Drug Class Small molecule

FDA Approval approved

Alternate Names:

C29076 NCI drug code

Alternate Names:

CHEMBL472 ChEMBL Drug ID

Publications:

Kharbanda C et al., 2015, Antidiabetic effect of novel benzenesulfonylureas as PPAR-γ agonists and their anticancer effect., Bioorg Med Chem Lett

Alternate Names:

D05LYX TTD Drug ID

Alternate Names:

GLIBENCLAMIDE GuideToPharmacology Ligand Name